<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00299702</url>
  </required_header>
  <id_info>
    <org_study_id>CR006121</org_study_id>
    <secondary_id>RISSCH4060</secondary_id>
    <nct_id>NCT00299702</nct_id>
  </id_info>
  <brief_title>Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia</brief_title>
  <official_title>A 2-year, Prospective, Blinded-rater, Open-label, Active-controlled, Multicenter, Randomized Study of Long-term Efficacy and Effectiveness Comparing Risperdal® Consta® and Abilify® (Aripiprazole) in Adults With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness of two antipsychotic medications,
      RisperdalÂ® ConstaÂ® versus AbilifyÂ®, over a 2-year treatment period in the long-term
      maintenance of patients with schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although many patients with schizophrenia currently take oral antipsychotic medications, it
      is estimated that up to 75% of them have difficulty adhering to the daily oral regimen.
      Long-acting injectable formulations of antipsychotics may eliminate the need for daily
      medication and enhance patient compliance with the treatment regimen. The purpose of this
      trial is to evaluate the long-term effectiveness of Risperdal® Consta®, a long-acting
      injectable antipsychotic medication, versus Abilify®, an oral antipsychotic medication in
      patients with schizophrenia. The study will include patients, who in the investigator's
      opinion may benefit from a change in their current antipsychotic medication due to
      insufficient effectiveness, side effects or difficulty in adhering to a daily dose regimen.
      This is an open-label, randomized study in which patients will have an equal chance of
      receiving treatment for up to 2 years with Risperdal® Consta®, administered in the muscles
      near the hip every 2 weeks, or Abilify®, taken orally once daily. The initial dose and
      subsequent dose of study drug will be determined by the investigator. The patient's current
      oral antipsychotic medication will be decreased over the first four weeks of the study and
      discontinued. During the study, investigators may adjust the dose of study drug or add new
      antipsychotic medications to treat worsening psychotic symptoms. Patients may continue on or
      have added, antidepressants, mood stabilizers (except carbamazepine), sedative hypnotics, or
      anxiolytic medications during the study. Patients will return to the doctor's office every
      two weeks to receive an injection of Risperdal® Consta® or another supply of Abilify®. During
      certain visits, patients will be asked questions which will help the investigator determine
      the severity of the patient's illness, how well the study drug is working, quality of life,
      reasoning, memory, judgement and perception and side effects that may be associated with
      schizophrenia or treatment. Safety evaluations include the incidence of adverse events during
      the study, vital signs and clinical laboratory tests (both blood and urine). The study
      hypothesis is that Risperdal® Consta® is superior to Abilify® in the long-term treatment of
      subjects with schizophrenia as measured by time to relapse and time in remission. Treatment
      with Risperdal® Consta® (administered in the muscle every 2 weeks) at a dose of 25, 37.5 or
      50 mg or Abilify® (administered orally daily) at a dose of 10-30 mg for 2 years.
      Investigators will determine the starting dose and may adjust the dosage of study drug during
      the study according to symptoms and treatment response.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Relapse</measure>
    <time_frame>Day 1 to relapse</time_frame>
    <description>Time to relapse was defined as the number of days from the date of first dose to the date of relapse, as determined by the Relapse Monitoring Board.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time in Remission</measure>
    <time_frame>Day 1 to last PANSS measurement</time_frame>
    <description>Time in remission for an individual subject was defined as the length of time (in days) that the remission criteria were maintained during the trial. Remission was defined as the simultaneous attainment of a score of 3 (mild), 2 (minimal), or 1 (absent) for all the following individual items from Positive and Negative Syndrome Scale (PANSS): delusions (P1), concept disorganization (P2), hallucinatory behavior (P3), unusual thought content (G9), mannerisms and posturing (G5), blunted affect (N1), passive/apathetic social withdrawal (N4), and lack of spontaneity and flow of conversation (N6).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">355</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Psychotic Disorders</condition>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abilify</intervention_name>
    <description>10-30 mg once daily for 104 weeks</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidal Consta</intervention_name>
    <description>25mg, 37.5mg, or 50mg every 2 weeks for 104 weeks</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with diagnosis of schizophrenia

          -  Patient has had at least 2 psychotic relapses in the two years prior to study entry

          -  patient is not adequately benefiting from their current antipsychotic medication

        Exclusion Criteria:

          -  Patients that have been hospitalized or had major medication changes within 2 months
             of study entry

          -  Patients currently experiencing, or who have experienced worsening of disease symptoms
             within 2 months of study entry

          -  Patients currently using clozapine or carbamazepine

          -  Patients who have undergone electroconvulsive therapy or depot antipsychotic treatment
             within 6 months prior to study entry

          -  pregnant or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L. C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Chile</country>
    <country>Denmark</country>
    <country>India</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2006</study_first_submitted>
  <study_first_submitted_qc>March 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2006</study_first_posted>
  <results_first_submitted>January 26, 2010</results_first_submitted>
  <results_first_submitted_qc>March 4, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 16, 2010</results_first_posted>
  <last_update_submitted>December 22, 2011</last_update_submitted>
  <last_update_submitted_qc>December 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2011</last_update_posted>
  <responsible_party>
    <name_title>Vice President, Medical Affairs</name_title>
    <organization>Ortho-McNeil Janssen Scientific Affairs, LLC</organization>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Relapse</keyword>
  <keyword>Remission</keyword>
  <keyword>Treatment Outcome</keyword>
  <keyword>long-acting injectable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first patient in was on February 28, 2006; last patient out was on January 26, 2009. Enrollment occurred across multiple sites in the United States, Argentina, Chile, and India and patients were enrolled from outpatient psychiatric clinics associated with private medical practices, private clinical trial sites, and academic medical centers.</recruitment_details>
      <pre_assignment_details>A Screening Visit (maximum of 14 days) prior to the Treatment Phase. Baseline included psychiatric exam, lab, ECG, and schizophrenia symptom rating scale. Subjects were permitted to remain on previous psychotropic medications (i.e., antipsychotic, antidepressant, mood stabilizer, anxiolytics) up to the first 4 weeks of the Treatment Phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Risperdal Consta</title>
          <description>25mg, 37.5mg, or 50mg every 2 weeks injection for 104 weeks</description>
        </group>
        <group group_id="P2">
          <title>Abilify</title>
          <description>10-30 mg once daily oral for 104 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="179"/>
                <participants group_id="P2" count="176"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
                <participants group_id="P2" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient Response</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Admin issues, sponsor decision, etc.</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Risperdal Consta</title>
          <description>25mg, 37.5mg, or 50mg every 2 weeks injection for 104 weeks</description>
        </group>
        <group group_id="B2">
          <title>Abilify</title>
          <description>10-30 mg once daily oral for 104 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="179"/>
            <count group_id="B2" value="176"/>
            <count group_id="B3" value="355"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="173"/>
                    <measurement group_id="B3" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.3" spread="11.66"/>
                    <measurement group_id="B2" value="37.8" spread="11.49"/>
                    <measurement group_id="B3" value="38" spread="11.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Relapse</title>
        <description>Time to relapse was defined as the number of days from the date of first dose to the date of relapse, as determined by the Relapse Monitoring Board.</description>
        <time_frame>Day 1 to relapse</time_frame>
        <population>explanatory ITT analysis data set (eITT) contains all subjects who had at least one administration of study drug as well as at least one follow-up efficacy measurement; includes assessments while the subject is on study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Risperdal Consta</title>
            <description>25mg, 37.5mg, or 50mg every 2 weeks injection for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>Abilify</title>
            <description>10-30 mg once daily oral for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Relapse</title>
          <description>Time to relapse was defined as the number of days from the date of first dose to the date of relapse, as determined by the Relapse Monitoring Board.</description>
          <population>explanatory ITT analysis data set (eITT) contains all subjects who had at least one administration of study drug as well as at least one follow-up efficacy measurement; includes assessments while the subject is on study drug.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131" lower_limit="100" upper_limit="197"/>
                    <measurement group_id="O2" value="113" lower_limit="99" upper_limit="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference in time to relapse</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.684</p_value>
            <p_value_desc>Hochberg procedure was used for adjusting multiple endpoint comparisons</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Insufficient number of subjects who had an event for median estimation.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time in Remission</title>
        <description>Time in remission for an individual subject was defined as the length of time (in days) that the remission criteria were maintained during the trial. Remission was defined as the simultaneous attainment of a score of 3 (mild), 2 (minimal), or 1 (absent) for all the following individual items from Positive and Negative Syndrome Scale (PANSS): delusions (P1), concept disorganization (P2), hallucinatory behavior (P3), unusual thought content (G9), mannerisms and posturing (G5), blunted affect (N1), passive/apathetic social withdrawal (N4), and lack of spontaneity and flow of conversation (N6).</description>
        <time_frame>Day 1 to last PANSS measurement</time_frame>
        <population>explanatory ITT analysis data set (eITT) contains all subjects who had at least one administration of study drug as well as at least one follow-up efficacy measurement; includes assessments while the subject is on study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Risperdal Consta</title>
            <description>25mg, 37.5mg, or 50mg every 2 weeks injection for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>Abilify</title>
            <description>10-30 mg once daily oral for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time in Remission</title>
          <description>Time in remission for an individual subject was defined as the length of time (in days) that the remission criteria were maintained during the trial. Remission was defined as the simultaneous attainment of a score of 3 (mild), 2 (minimal), or 1 (absent) for all the following individual items from Positive and Negative Syndrome Scale (PANSS): delusions (P1), concept disorganization (P2), hallucinatory behavior (P3), unusual thought content (G9), mannerisms and posturing (G5), blunted affect (N1), passive/apathetic social withdrawal (N4), and lack of spontaneity and flow of conversation (N6).</description>
          <population>explanatory ITT analysis data set (eITT) contains all subjects who had at least one administration of study drug as well as at least one follow-up efficacy measurement; includes assessments while the subject is on study drug.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="373.5" spread="282.6"/>
                    <measurement group_id="O2" value="356.7" spread="291.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference in time in remission between the two treatment groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.646</p_value>
            <p_value_desc>Hochberg procedure was used for adjusting multiple endpoint comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported as treatment emergent if the onset date is before or within 49 days of last dose of RISPERDAL CONSTA or before or within 30 days of last dose of Abilify.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>RISPERDAL CONSTA</title>
          <description>25mg, 37.5mg, or 50mg every 2 weeks injection for 104 weeks</description>
        </group>
        <group group_id="E2">
          <title>Abilify</title>
          <description>10-30 mg once daily oral for 104 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>GOITRE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ANAL FISSURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>IRRITABLE BOWEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>MELAENA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>MULTIPLE DRUG OVERDOSE ACCIDENTAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>DIABETIC KETOACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>LEIOMYOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>AKATHISIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>PSYCHOTIC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>SCHIZOPHRENIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>AGGRESSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>DEPRESSION SUICIDAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>AFFECT LABILITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>ALCOHOLISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>COMPLETED SUICIDE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>DRUG DEPENDENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>HOMICIDAL IDEATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>MANIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="141" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERPROLACTINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>SALIVARY HYPERSECRETION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>WEIGHT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>AKATHISIA</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>HYPERSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>SEDATION</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>PSYCHOTIC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>SCHIZOPHRENIA</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>RESTLESSNESS</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>SLEEP DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>15% of subjects did not meet stability inclusion criteria; many received supplemental antipsychotics post-randomization; biweekly visits may have increased aripiprazole adherence; numerous early dropouts may have led to dependent censoring and bias.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Therapeutic Area Lead</name_or_title>
      <organization>Ortho-McNeil, Inc. N America Pharm CNS/IM</organization>
      <phone>609-730-3693</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

